Vaccitech to Present an Update on Its Chronic HBV Infection Immunotherapeutic Program at The World Vaccine Congress Europe
October 13, 2021 08:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech to Present at Upcoming September Investor conferences
September 09, 2021 08:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
August 12, 2021 08:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter, ended June 30, 2021, and provided an overview of...
Vaccitech to Present at the William Blair Biotech Focus Conference 2021
July 08, 2021 08:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, July 08, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments
June 14, 2021 17:49 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech to Present at the Jefferies Virtual Healthcare Conference
June 01, 2021 08:00 ET
|
Vaccitech Limited
OXFORD, United Kingdom, June 01, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Announces Closing of $110.5 Million Initial Public Offering
May 04, 2021 17:07 ET
|
Vaccitech Limited
OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics...
Vaccitech Announces Pricing of Initial Public Offering
April 29, 2021 18:49 ET
|
Vaccitech Limited
OXFORD, United Kingdom, April 29, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors
March 22, 2021 04:00 ET
|
Vaccitech Limited
OXFORD, United Kingdom, March 22, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection
March 18, 2021 03:00 ET
|
Vaccitech Limited
OXFORD, United Kingdom, March 18, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines...